The Finland-based drug major Orion Corporation has filed a lawsuit in the United States against domestic drug major Wockhardt for challenging the patents on its brand Stalevo, used for the treatment of Parkinson's disease.
This is the company's third international buyout in the last 12 months. Last year in October, the company had acquired Pinewood, the largest generic firm in Ireland and the biggest supplier of liquid generic products in the UK. Wockhardt had also bought Negma, the fourth largest independent pharmaceutical firm in France in May.
Earlier this week, the company postponed the announcement of its results for the year-ended December 31, 2008, as the statutory audit could not be completed because of restructuring of certain of its businesses and subsidiaries. In a major top management rejig, the company's chairman and managing director Habil Khorakiwala, stepped down as managing director.
Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.
Beleaguered drugmaker Wockhardt has a new management team in place to implement a three-year strategic plan to get back on track. The company has seen at least four senior-level exits in the last few months.
Wockhardt Ltd said on Thursday it has received approval from USFDA for marketing antibiotic, Clarithromycin tablets, in the US market.
After recovering from issues such as defaults on foreign currency convertible bonds and piling debts, pharmaceutical major Wockhardt has been on the slow lane through the last six months, following warnings from global regulators such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency.
Indian drug maker, Wockhardt Ltd on Friday said it has acquired Dumex India Pvt Ltd along with its two products Protinex and Farex from the Netherlands-based Royal Numico NV for an undisclosed sum.
The FDA had imposed a ban on the company's Waluj plant in May.
Wockhardt has received United States Food & Drug Administration approval to market Zonisamide capsules.
Wockhardt is recalling select drugs in the US, which were under import restrictions from the USFDA.
If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.
Wockhardt hospitals has launched the "patient care rights" in India, becoming the first hospital in the country to launch such an initiative aimed at establishing the rights of every person who is in receipt of medical care at its facilities to prote
Contests patent application for Nadifloxacin along with Hyderabad's Hetero.
Pharma major Wockhardt is looking to acquire a German firm this year to strengthen its position in Europe and has set an overall sales target of Rs 100 crore (Rs 1 billion) from its biotech products for this year.
The ruling came as a consent order from Sebi following an investigation on insider trading in the shares of Wockhardt between September 1, 1998 and December 31, 1999. A Wockhardt spokesperson declined to comment.
When you're stressed, your body releases hormones like cortisol and adrenaline, which can interfere with your digestion process and cause excessive acid production, says Dr Aklesh Tandekar, head-consultant critical care, Wockhardt Hospitals.
Focus to continue on anti-infectives market abroad; no plan for out-licensing
Wockhardt said it is launching the product immediately in the US market.
The company has received a communication from the Medicines and Healthcare Products Regulatory Agency, United Kingdom, whereby the agency has decided to withdraw the previously issued GMP Certificate to the company's manufacturing facility situated at Kadaiya, Nani Daman, Wockhardt said in a filing to the Bombay Stock Exchange.
Wockhardt, the Mumbai-based leading pharmaceutical and biotechnology company that is struggling to repay its nearly Rs 900-crore
The court will hear the matter on September 6.
Its factory in Chikalthana in western India was last month hit by the British drug regulator's curb on imports from the plant over manufacturing deficiencies.
Front-running is a fraudulent practice where traders exploit advance knowledge of large client orders for personal profit.
Wockhardt Ltd has signed an In-licensing agreement with UK-based LSI to market Vitix, a drug used for treating pigmentation disorder.
The court's stand is expected to help Wockhardt conclude the deal within a month's time.
Wockhardt, in a release issued to the National Stock Exchange on Tuesday, has announced the acquisition of CP Pharmaceuticals (Holdings) along with its subsidiaries.
Pharmaceutical and biotechnology major, Wockhardt has received final approval from the United States Food & Drug Administration for marketing the cardiac drug.
Wockhardt Ltd has received tentative approval from the USFDA for anti-epileptic drug, Divalproex Sodium delayed-release tablets.
Two pharma majors Novartis and Wockhardt have adopted 'wait and watch' policy with regard to opposition over the yet to be granted patent to their respective drugs.
Pharma major Wockhardt on Wednesday said it has launched Tamsulosin capsules, indicated for problem of prostate enlargement, in the US market on the day one of the expiry of patent covering the drug.
Met with lukewarm response from a volatile market, Wockhardt Hospitals withdrew its IPO. It received bids only for 19.5%.
The company said it is launching the product immediately
